Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the ...

Novavax Inc. closed 74.96% below its 52-week high of $23.86, which the company reached on June 6th.

Novavax (NASDAQ:NVAX) shares climbed ~35% in the premarket on Thursday after the COVID-19 vaccine maker lifted its full-year ...

Novavax Inc (NVAX) reports a dramatic revenue increase and strategic collaborations, while navigating regulatory hurdles and ...

QBTS: D-Wave Quantum shares are rallying after the company beat analysts' estimates and reported record quarterly revenue ...

Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsLuis Sanay - Vice President, Investor ...

Novavax stock is limping into earnings season. Its upcoming May 8 Q1 results might be the last shot at redemption. Once hailed as a pandemic hero, the biotech firm is now fighting ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Stoke Therapeutics (STOK – Research Report), Novavax (NVAX – Research Report) ...

On a per-share basis, the Gaithersburg, Maryland-based company said it had net income of $2.93. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...

Novavax Inc. closed 73.72% short of its 52-week high of $23.86, which the company achieved on June 6th.